Hypoxia-responsive core-cross-linked supramolecular nanoprodrug based on dendritic drug-drug conjugates for synergetic anticancer therapy.

IF 10.6 1区生物学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Journal of Nanobiotechnology Pub Date : 2025-04-26 DOI:10.1186/s12951-025-03394-y

Yue Ding, Yu Xie, Liangshun Zheng, Mingguang Lin, Yihai Shi, Tingting Chen, Chang Du, Jin Ding, Beifang Ning

{"title":"Hypoxia-responsive core-cross-linked supramolecular nanoprodrug based on dendritic drug-drug conjugates for synergetic anticancer therapy.","authors":"Yue Ding, Yu Xie, Liangshun Zheng, Mingguang Lin, Yihai Shi, Tingting Chen, Chang Du, Jin Ding, Beifang Ning","doi":"10.1186/s12951-025-03394-y","DOIUrl":null,"url":null,"abstract":"Background: Recently, the strategy of self-assembling dendritic drug-drug conjugates into supramolecular nanoprodrug was widely explored in biomedical applications. Herein, we construct a hypoxia-responsive core-cross-linked supramolecular nanoprodrug (CSN-IR806/CB) based on a dendritic drug-drug conjugate.Methods: We prepared a hypoxia-responsive dendritic drug-drug conjugates IR806-(Azo-CB)4, which was combined with β-cyclodextrin-pendant poly(ethylene glycol)-block-poly(glutamic acid) block copolymer (PEG-PGlu-CD) to construct the core-cross-linked supramolecular nanoprodrug (CSN-IR806/CB) with enhanced physiological stability through the synergy of π-π stacking interaction, host-guest complexation, hydrogen bonds, and hydrophobic interaction.Results: The near-infrared (NIR) light irradiation of the CSN-IR806/CB treated tumor cells induced IR806-mediated PDT and PTT, and aggravated hypoxia, which triggered the disassembly of CSN-IR806/CB and the subsequent release of activated CB for synergetic cancer cell killing.Conclusions: The CSN-IR806/CB can realize a synergistic triple therapeutic effect of photothermal therapy (PTT), photodynamic therapy (PDT), and chemotherapy (CT; i.e., PTT-PDT-CT).","PeriodicalId":16383,"journal":{"name":"Journal of Nanobiotechnology","volume":"23 1","pages":"316"},"PeriodicalIF":10.6000,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12032639/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nanobiotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1186/s12951-025-03394-y","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Recently, the strategy of self-assembling dendritic drug-drug conjugates into supramolecular nanoprodrug was widely explored in biomedical applications. Herein, we construct a hypoxia-responsive core-cross-linked supramolecular nanoprodrug (CSN-IR806/CB) based on a dendritic drug-drug conjugate.

Methods: We prepared a hypoxia-responsive dendritic drug-drug conjugates IR806-(Azo-CB)₄, which was combined with β-cyclodextrin-pendant poly(ethylene glycol)-block-poly(glutamic acid) block copolymer (PEG-PGlu-CD) to construct the core-cross-linked supramolecular nanoprodrug (CSN-IR806/CB) with enhanced physiological stability through the synergy of π-π stacking interaction, host-guest complexation, hydrogen bonds, and hydrophobic interaction.

Results: The near-infrared (NIR) light irradiation of the CSN-IR806/CB treated tumor cells induced IR806-mediated PDT and PTT, and aggravated hypoxia, which triggered the disassembly of CSN-IR806/CB and the subsequent release of activated CB for synergetic cancer cell killing.

Conclusions: The CSN-IR806/CB can realize a synergistic triple therapeutic effect of photothermal therapy (PTT), photodynamic therapy (PDT), and chemotherapy (CT; i.e., PTT-PDT-CT).

查看原文本刊更多论文

基于树突状药物-药物偶联物的低氧反应核交联超分子纳米前药协同抗癌治疗。

背景：近年来，树突状药物-药物偶联物自组装成超分子纳米前药的策略在生物医学领域的应用得到了广泛的探索。在此，我们构建了一个基于树突药物-药物偶联物的低氧响应核心交联超分子纳米前药（CSN-IR806/CB）。方法：制备低氧响应树突状药物-药物偶联物IR806-(Azo-CB)4，与β-环糊精悬置聚乙二醇-嵌段聚谷氨酸嵌段共聚物（PEG-PGlu-CD）结合，通过π-π叠加作用、主客体络合作用、氢键和疏水相互作用等协同作用，构建具有增强生理稳定性的核心交联超分子纳米前药（CSN-IR806/CB）。结果：近红外（NIR）光照射CSN-IR806/CB处理的肿瘤细胞，诱导ir806介导的PDT和PTT，并加重缺氧，触发CSN-IR806/CB的分解和随后释放活化的CB，协同杀伤癌细胞。结论：CSN-IR806/CB可实现光热治疗（PTT）、光动力治疗（PDT）、化疗(CT；也就是说,PTT-PDT-CT)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Nanobiotechnology BIOTECHNOLOGY & APPLIED MICROBIOLOGY-NANOSCIENCE & NANOTECHNOLOGY

CiteScore

13.90

自引率

4.90%

发文量

493

审稿时长

16 weeks

期刊介绍： Journal of Nanobiotechnology is an open access peer-reviewed journal communicating scientific and technological advances in the fields of medicine and biology, with an emphasis in their interface with nanoscale sciences. The journal provides biomedical scientists and the international biotechnology business community with the latest developments in the growing field of Nanobiotechnology.